253 related articles for article (PubMed ID: 9299637)
21. CRF receptor type 1 (but not type 2) located within the amygdala plays a role in the modulation of anxiety in mice exposed to the elevated plus maze.
Cipriano AC; Gomes KS; Nunes-de-Souza RL
Horm Behav; 2016 May; 81():59-67. PubMed ID: 27060334
[TBL] [Abstract][Full Text] [Related]
22. Anxiolytic-like effects of antisauvagine-30 in mice are not mediated by CRF2 receptors.
Zorrilla EP; Roberts AJ; Rivier JE; Koob GF
PLoS One; 2013; 8(8):e63942. PubMed ID: 24015170
[TBL] [Abstract][Full Text] [Related]
23. Anxiogenic-like effect of corticotropin-releasing factor receptor 2 antisense oligonucleotides infused into rat brain.
Isogawa K; Akiyoshi J; Tsutsumi T; Kodama K; Horinouti Y; Nagayama H
J Psychopharmacol; 2003 Dec; 17(4):409-13. PubMed ID: 14870953
[TBL] [Abstract][Full Text] [Related]
24. Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome.
Nozu T; Okumura T
J Gastroenterol; 2015 Aug; 50(8):819-30. PubMed ID: 25962711
[TBL] [Abstract][Full Text] [Related]
25. Lack of interaction between etifoxine and CRF1 and CRF2 receptors in rodents.
Verleye M; André N; Gillardin JM
Neurosci Res; 2006 Sep; 56(1):53-60. PubMed ID: 16769145
[TBL] [Abstract][Full Text] [Related]
26. The role of CRF2 receptors in corticotropin-releasing factor- and urocortin-induced anorexia.
Smagin GN; Howell LA; Ryan DH; De Souza EB; Harris RB
Neuroreport; 1998 May; 9(7):1601-6. PubMed ID: 9631473
[TBL] [Abstract][Full Text] [Related]
27. Regulation of corticotropin-releasing factor type 1 (CRF1) receptor messenger ribonucleic acid in the paraventricular nucleus of rat hypothalamus by exogenous CRF.
Mansi JA; Rivest S; Drolet G
Endocrinology; 1996 Nov; 137(11):4619-29. PubMed ID: 8895325
[TBL] [Abstract][Full Text] [Related]
28. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain.
Sánchez MM; Young LJ; Plotsky PM; Insel TR
J Comp Neurol; 1999 Jun; 408(3):365-77. PubMed ID: 10340512
[TBL] [Abstract][Full Text] [Related]
29. Differential mechanisms of CRF1 and CRF2 receptor functions in the amygdala in pain-related synaptic facilitation and behavior.
Fu Y; Neugebauer V
J Neurosci; 2008 Apr; 28(15):3861-76. PubMed ID: 18400885
[TBL] [Abstract][Full Text] [Related]
30. CRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cues.
Risbrough VB; Geyer MA; Hauger RL; Coste S; Stenzel-Poore M; Wurst W; Holsboer F
Neuropsychopharmacology; 2009 May; 34(6):1494-503. PubMed ID: 19020499
[TBL] [Abstract][Full Text] [Related]
31. Distribution of corticotropin-releasing factor (CRF) receptor binding in the mouse brain using a new, high-affinity radioligand, [
Tan LA; Vaughan JM; Perrin MH; Rivier JE; Sawchenko PE
J Comp Neurol; 2017 Dec; 525(18):3840-3864. PubMed ID: 28842924
[TBL] [Abstract][Full Text] [Related]
32. [Effect of corticotropin releasing factor(CRF) on somatic pain sensitivity in conscious rats: involvement of CRF1 and CRF2 receptors].
Iarushkina NI; Bagaeva TR; Filaretova LP
Ross Fiziol Zh Im I M Sechenova; 2014 Nov; 100(11):1287-96. PubMed ID: 25665407
[TBL] [Abstract][Full Text] [Related]
33. CRF1 and CRF2 receptors in the bed nucleus of the stria terminalis modulate the cardiovascular responses to acute restraint stress in rats.
Oliveira LA; Almeida J; Benini R; Crestani CC
Pharmacol Res; 2015; 95-96():53-62. PubMed ID: 25829333
[TBL] [Abstract][Full Text] [Related]
34. Central CRF2 receptor antagonism reduces anxiety states during amphetamine withdrawal.
Reinbold ED; Scholl JL; Oliver KM; Watt MJ; Forster GL
Neurosci Res; 2014 Dec; 89():37-43. PubMed ID: 25205625
[TBL] [Abstract][Full Text] [Related]
35. The effects of CRF and the urocortins on the hippocampal acetylcholine release in rats.
Pintér D; Balangó B; Simon B; Palotai M; Csabafi K; Dobó É; Ibos KE; Bagosi Z
Neuropeptides; 2021 Aug; 88():102147. PubMed ID: 33932861
[TBL] [Abstract][Full Text] [Related]
36. Spontaneous withdrawal from the triazolobenzodiazepine alprazolam increases cortical corticotropin-releasing factor mRNA expression.
Skelton KH; Nemeroff CB; Owens MJ
J Neurosci; 2004 Oct; 24(42):9303-12. PubMed ID: 15496666
[TBL] [Abstract][Full Text] [Related]
37. Importance of CRF receptor-mediated mechanisms of the bed nucleus of the stria terminalis in the processing of anxiety and pain.
Tran L; Schulkin J; Greenwood-Van Meerveld B
Neuropsychopharmacology; 2014 Oct; 39(11):2633-45. PubMed ID: 24853772
[TBL] [Abstract][Full Text] [Related]
38. Constitutive Increases in Amygdalar Corticotropin-Releasing Factor and Fatty Acid Amide Hydrolase Drive an Anxious Phenotype.
Natividad LA; Buczynski MW; Herman MA; Kirson D; Oleata CS; Irimia C; Polis I; Ciccocioppo R; Roberto M; Parsons LH
Biol Psychiatry; 2017 Oct; 82(7):500-510. PubMed ID: 28209423
[TBL] [Abstract][Full Text] [Related]
39. Tonic modulation of anxiety-like behavior by corticotropin-releasing factor (CRF) type 1 receptor (CRF1) within the medial prefrontal cortex (mPFC) in male mice: role of protein kinase A (PKA).
Miguel TT; Gomes KS; Nunes-de-Souza RL
Horm Behav; 2014 Jul; 66(2):247-56. PubMed ID: 24848364
[TBL] [Abstract][Full Text] [Related]
40. Corticotropin-releasing factor antagonists, binding-protein and receptors: implications for central nervous system disorders.
Heinrichs SC; De Souza EB
Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Dec; 13(4):541-54. PubMed ID: 10903813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
